Shares of Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) surged as much as 72% after agreeing to be acquired by Seattle Genetics, Inc. (NASDAQ:SGEN) for $10 …
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that it intends to offer and sell shares of its common stock and Series E convertible preferred …
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced an overview of recent progress for its investigational drug portfolio in addition to several anticipated key objectives …
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced the appointment of Marc L. Lesnick, Ph.
Cowen analyst Boris Peaker weighed in on Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) with a few insights after the company announced that following a recent meeting with …
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that following a recent meeting with the U.S.
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced the presentation of clinical activity of tucatinib, its investigational, highly selective small molecule HER2 inhibitor, in combination therapy …
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that its board of directors has approved a plan for a reverse split of the Company’s common stock …
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC), a clinical-stage biopharmaceutical company, announced that the United States Adopted Names (USAN) Council and the International Nonproprietary Names (INN) …
Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the ONT-380 program in advanced HER2+ metastatic breast cancer has received Fast Track designation …